1Q20 Research

ImmunoGen (IMGN): Mirvetuximab shows promise in 2nd Line Treatment of Platimum-Resistant Ovarian Cancer
Nektar Therapeutics (NKTR): Bempegadesleukin ("bempeg", NKTR-214) - potential 1st Line Treatment in Metastatic Melanoma
UroGen Pharma's (URGN) Jelmyto (UGN-101, UGN-102) - Transformative Non-Surgical Treatment Option in Bladder Cancer

4Q19 Research

4Q19 Exelixis (EXCL): Threshold Limits to Advance Cabozantinib to Front-Line Setting in Renal Cell Carcinoma (RCC)
MorphoSys' (MOR) tafasitamab (MOR208) - an effective treatment option in r/r DLBCL

3Q19 Research

3Q19 Non-Small Cell Lung Cancer (NSCLC) Market
3Q19 Solid Tumor - Greater Role for PARP Inhibitors
​3Q19 Competitive Positioning in Hematologic Cancer: Lymphoma

2Q19 Research

2Q19 Iovance Biotherapeutics (IOVA)
2Q19 Seattle Genetics (SGEN)

1Q19 Research

​1Q19 Sangamo Therapeutics (SGMO)
1Q19 Ionis Pharmaceuticals (IONS) & Alnylam Pharmaceuticals (ALNY)
1Q19 Sarepta Therapeutics (SRPT)
1Q19 Nektar Therapeutics (NKTR)

4Q18 Research

4Q18 Pharma / Biotech

3Q18 Research

3Q18 Pharma / Biotech Initiation

1Q18 Research

2Q18 Retail Pharmacy / PBM
1Q18 Retail Pharmacy / PBM
1Q18 Drug Wholesalers
1Q18 Health Payers
Healthcare Mergers (CVS/Aetna & Cigna/ESRX): Puts & Takes

4Q17 Research

SECTOR INITIATION
Retail Pharmacy Initiation & 4Q17